REG - EKF Diagnostics Hldg - Long Term Incentive Plan

EKF Diagnostics HoldingsAnnouncement

Today 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250916:nRSP4126Za&default-theme=true

RNS Number : 4126Z  EKF Diagnostics Holdings PLC  16 September 2025

EKF Diagnostics Holdings plc

("EKF" or "the Company")

 

Long Term Incentive Plan

 

The Board recognises the importance of incentivising and rewarding the
performance of its key executives, and having considered the views of certain
of its shareholders, recently tasked the remuneration committee to recommend
to the Board an appropriate long term incentive plan ("LTIP") for its senior
executives.

 

The Board, following the recommendation of the remuneration committee and
after consulting its advisers, has today made the following award (the
"Award") to Gavin Jones (Chief Executive Officer) under the Company's newly
established LTIP that was adopted on 9 September 2025:

 

 Individual   Position                 Type of Award                     Number of ordinary shares subject to LTIP award
 Gavin Jones  Chief Executive Officer  LTIP award - nominal cost option  500,000

 

The Award has a performance period from the grant date to the third
anniversary of the grant date and are subject to the following performance
criteria.

 

The Award shall vest on a sliding scale depending on the total percentage
growth of Adjusted EBITDA per share over the Performance Period, as follows:

(i)            Growth of 25% or higher: 100% of the Award vests.

(ii)           Between 10% and 25% growth: Vesting shall occur on a
straight-line basis between 25% and 100%.

(iii)          10% growth: 25% of the Award vests; or

(iv)         Below 10% growth: 0% of the Award vests.

 

Comment from the Chair of the Remuneration committee, Jenny Winter:

"It is important that Gavin is rewarded in a way which links his performance
with shareholder value creation. I am satisfied that these incentivisation
arrangements achieve that objective."

 

 

 EKF Diagnostics Holdings plc                                   www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair                                  via Walbrook PR
 Gavin Jones, Chief Executive Officer
 Stephen Young, Chief Financial Officer

 Singer Capital Markets (Nominated Adviser & Broker)            Tel: +44 (0)20 7496 3000
 Phil Davies / Oliver Platts

 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
 Paul McManus / Alice Woodings    Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com/) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

·    Point-of-Care analysers in the key areas of Hematology and
Diabetes.

·    Life Sciences services provide specialist manufacture of enzymes
and custom products for use in diagnostic food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

 

      Details of the person discharging managerial responsibilities / person closely
      associated

 a)   Name                                                         Gavin Jones

 2    Reason for the notification

 a)   Position/status                                              Chief Executive Officer

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         EKF Diagnostics Holdings plc

 b)   LEI                                                          213800DXTF3EAUK1AR05

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 1 pence each

      Identification code                                          GB0031509804

 b)   Nature of the transaction                                    Grant of options over ordinary shares pursuant to the Company's LTIP

 c)   Price(s) and volume(s)

                                                                                       Price(s)            Volume(s)
                                                                                       1p                  500,000

 d)   Aggregated information

      - Aggregated volume                                          n/a

      - Price

 e)   Date of the transaction                                       16 September 2025

 f)   Place of the transaction                                     Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFIDASIELIE